Articles

This LCD has been revised to remove the language related to place of service (POS) from the "Indications and Limitations of Coverage and/or Medical Necessity" section of the LCD.

The LCD and the coding guidelines attachment were revised to extend the therapy cap exception process through December 31, 2009 based on the Medicare Improvements for Patients and Providers Act of 2008.

The LCD for Bortezomib (Velcade®) was revised to delete the requirement for at least one prior therapy for treatment of patients with multiple myeloma in the “Indications and Limitations of Coverage and/or Medical Necessity” section of the LCD.

This article provides clarification on how to bill for aqueous drainage devices for the treatment of glaucoma.

Have you received a request from Medicare for medical records, or do you have questions regarding medical record review? Read this article for more information.

This article provides clarification of the non-coverage of 99199 Pulsatile Intravenous Insulin Therapy (PIVIT).

This LCD has been revised to add CPT code 42299 (Palatal implants [Pillar™]) to the list of procedures under the “local noncoverage decisions” section of the LCD. Palatal implants (Pillar™) are considered experimental and investigational.

This LCD was revised to add CPT codes 0190T and 0191T under the ‘CPT/HCPCS Codes’, ‘Local Noncoverage Decisions, Procedures’ section of the LCD, as these procedures are considered investigational.

The coding guidelines attachment for IDTF has been revised for the "Technician Qualification Requirements" for procedure codes 78000-78816 listed in the 'Credentialing Matrix' to delete the requirement of 'State License: General Radiographer'.

The LCD was revised to clarify the frequency of courses of treatment allowed, documentation guidelines to support frequency of courses of treatment, conservative treatment, and the use of imaging when administering viscosupplementation.

This new local coverage determination (LCD) was written to outline when FCSO will consider the application of gene expression profiling using Oncotype DXTM as medically reasonable and necessary.

This new local coverage determination (LCD) has been written to outline the appropriate indications and limitations for Ferrlecit® and Venofer®.

The LCD for Trastuzumab (Herceptin®) was revised to update language for additional approved indications based on the Food and Drug Administration (FDA) drug label.

This article provides clarification on the correct billing of VIDAZA (J9025) and chemotherapy administration code 96401 (Chemotherapy administration, subcutaneous or intramuscular; non-hormonal).

This article provides clarification on how to bill for Quantitative Sensory Testing (QST) when using the Xilas vibration perception threshold (VPT) meter.

LCD was revised to add language based on change request 5921, transmittal 88, dated May 7, 2008. This change request outlines updated therapy personnel qualifications and revised recertification requirements.

Link to the CMS Medicare Coverage Database. The following results include only currently in effect documents.